x
English
My account

Trade Hikma Pharmaceuticals PLC - HIK CFD

1m
5m
15m
30m
1H
4H
1D
1W

Trader sentiment

% Buyers % Sellers
  • Long position overnight fee -0.0157%
  • Short position overnight fee -0.0117%
  • Overnight fee time 21:00 (UTC)
  • Min traded quantity 1
  • Currency GBP
  • Margin 20%
  • Stock exchange United Kingdom of Great Britain and Northern Ireland
  • Trading hours (UTC)
    Mon - Fri: 07:00 - 11:00
    11:03 - 15:30
  • Commission on trade 0%

Hikma (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. In all, the company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics. Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The most popular products from the Branded division are: Amoclan, Omnisef, Blopress, Suprax and other. Hik share price is set and traded on the London Stock Exchange (LSE). The company constitutes the FTSE 100 and FTSE 350 Indices. 

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, It became the first Arab company to export pharmaceutical products to the US. The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquiring helped Hikma to establish itself as the world’s leading provider in its industry. 

Hikma made an initial public offering on 11 November 2005, and Hik share price was listed on the London Stock Exchange for the first time, raising gross proceeds of $124 million.

In May 2014, Hikma Pharmaceuticals agreed to purchase assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, drastically increasing its presence in the injected medicine market.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma position in a non-injectables business in the US market.

Hikma have been recognized as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a raw: from 2014 to 2017.

Follow Capital.com to stay tuned to the Hikma share price.

Learn more Hide

How we make money?

Capital.com makes the majority of it’s money through the spread, the difference between the buy and sell price.

Trade shares with leverage

Shares are available to trade with up to 5:1 leverage. Start trading with as little as $100 to control a position of $500

Shares CFDs

  • Trade 24/5 on a wide range of shares

  • Buy and sell shares to take advantage of rises and falls in price

Profit and loss control

You can easily define Stops and Limits to request positions to close at a specified price.

Set up price alerts to be informed of big moves.

You might be interested in